Related Experiment Video

Updated: Jul 3, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure

Theodor H Lippert1, Hans-Jörg Ruoff, Manfred Volm

  • 1Medical Faculty, University of Tuebingen, Germany. Theodor-Lippert@web.de

Arzneimittel-Forschung
|August 6, 2008
PubMed

Insights

Drug resistance significantly hinders cancer chemotherapy success. Early diagnostic tests are crucial for personalized cancer therapy, avoiding toxic side effects and optimizing treatment by identifying resistance sooner.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomedical Diagnostics

Background:

  • Drug resistance is a primary cause of chemotherapy failure, stemming from complex, variable biological mechanisms.
  • Both pre-existing (intrinsic) and acquired drug resistance are significant clinical challenges.
  • Current methods detect resistance late in treatment, leading to prolonged exposure to ineffective and toxic drugs.

Purpose of the Study:

  • To highlight the critical need for early diagnostic tests for cancer drug resistance.
  • To emphasize the importance of integrating resistance assays into clinical practice for personalized cancer therapy.
  • To advocate for intensified research into overcoming drug resistance.

Main Methods:

  • Review of current clinical practices regarding cancer drug resistance detection.
  • Analysis of the limitations of existing chemotherapy and targeted drug approaches concerning resistance.
  • Discussion of the potential benefits of early resistance diagnosis.

Main Results:

  • Drug resistance, a major cause of chemotherapy failure, can be intrinsic or acquired.
  • Even targeted therapies are subject to resistance and severe side effects.
  • Early detection of resistance is essential for optimizing treatment and avoiding toxicity.

Conclusions:

  • Early diagnosis of drug resistance is indispensable for effective and personalized cancer therapy.
  • Integrating available resistance assays into clinical practice is necessary.
  • Further research is urgently needed to address this neglected area.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...